Omega-3 Fatty Acids May Slow Prostate Cancer Progression and Reduce Mortality Risk

Strategic Insights -

Investigating the relationship between Omega-3 fatty acid intake and the risk of prostate cancer, a recent study published in Frontiers in Nutrition has found a linear relationship between the two. While the study suggests that higher intakes of Omega-3 fatty acids may slow prostate cancer progression and reduce mortality risk, it also notes a threshold effect, where intakes below 0.4 g/day may reduce mortality risk, but higher intakes potentially increase the risk.

Key Takeaways:

  • The study, conducted using data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial, included 30,552 male participants aged 55-74 years.
  • The results indicated a linear relationship between Omega-3 fatty acid intake and the overall risk of prostate cancer (HR for highest vs. lowest quintile: 0.90, 95% CI: 0.81-1.00, p = 0.053).
  • For prostate cancer mortality, a non-linear relationship was observed, with a potential U-shaped association (p = 0.009).
  • The risk of death decreased as intake increased below 0.4 g/d, with a hazard ratio of 0.67 (95% CI: 0.49-0.91, p = 0.011) for the second quintile compared to the lowest quintile.
  • However, intake exceeding 0.4 g/d was associated with an increased risk (HR for highest quintile: 0.70, 95% CI: 0.52-0.95, p = 0.021).

Statistics:

  • 30,552 male participants aged 55-74 years were included in the study.
  • The median follow-up time was 7 years.
  • Patients with intakes below 0.4 g/d had a reduced mortality risk.
  • Patients with intakes exceeding 0.4 g/d had an increased risk of death.

Sources:

  • NewsRx. New Findings from Fujian Medical University in the Area of Ovarian Cancer Reported (Dietary Omega-3 intake may slow prostate cancer progression and reduce mortality risk: evidence from prostate, lung, colorectal, and ovarian cancer screening ...). OBGYN & Reproduction Week. August 18, 2025; p 459.
  • Frontiers in Nutrition. "Dietary Omega-3 intake may slow prostate cancer progression and reduce mortality risk: evidence from prostate, lung, colorectal, and ovarian cancer screening trial." Volume 12, 2025.